Patenting and Personal Genomics: 23andMe Receives its First Patent, and Plenty of Questions
By Dan Vorhaus,
Genomics Law Report
| 06. 01. 2012
Earlier this week 23andMe, the Silicon Valley-based personal genomics company, was awarded its first patent: US Patent Number 8,187,811, entitled “Polymorphisms associated with Parkinson’s disease”.
23andMe co-founder Anne Wojcicki announced the issuance of the patent via a post on the company’s blog late Monday evening, attempting to strike a tenuous balance between her company’s oft-championed philosophical devotion to providing individuals with “unfettered access to their genomes” and its desire to commercialize the genomic information so many of those very same individuals have shared, free of charge, with 23andMe. With its new patent, 23andMe also injected itself into the middle of what Wojcicki herself described as the “hot debate” surrounding the patentability of “inventions related to genetics.” Wojcicki’s announcement appeared to catch more than a few of the company’s customers by surprise, sparking concern about the company’s intentions on 23andMe’s blog, Twitter and elsewhere, along with rapid and pointed commentaries from Stuart Hogarth and Madeleine Ball, among others.
Of the various questions asked of and about 23andMe and its new patent, these may be the three most common:...
Related Articles
By Megan Agnew, The Times | 09.15.2024
Faith Hartley always wanted two girls — a blonde and a redhead. “I thought, I’ll have one that looks like me,” says Hartley, 35, smoothing her golden hair in the Los Angeles valley home she shares with her husband, Neil...
By Emily R. Klancher Merchant, Los Angeles Review of Books | 08.22.2024
IN THE Operation Varsity Blues scandal of 2019, 50 wealthy parents were charged with trying to get their children into elite universities through fraudulent means. The story dramatically demonstrated the lengths to which some parents will go to ensure their...
By Julia Brown, The Conversation | 08.16.2024
With their primary goal to advance scientific knowledge, most scientists are not trained or incentivized to think through the societal implications of the technologies they are developing. Even in genomic medicine, which is geared toward benefiting future patients, time and...
By Smriti Mallapaty, Nature | 09.11.2024
Under his microscope, Jun Wu could see several tiny spheres, each less than 1 millimetre wide. They looked just like human embryos: a dark cluster of cells surrounded by a cavity, and then another ring of cells.
But Wu, a...